Informatie:
Fout:
ID
15602
Beschrijving
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00038610
Link
https://clinicaltrials.gov/show/NCT00038610
Trefwoorden
Versies (1)
- 04-06-16 04-06-16 -
Geüploaded op
4 juni 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Leukemia NCT00038610
Eligibility Leukemia NCT00038610
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00038610
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ph-positive all
Item
1. diagnosis of previously untreated ph-positive all or previously treated in cr after 1-2 courses of therapy or failure after one course of induction chemotherapy without imatinib mesylate.
boolean
C1960397 (UMLS CUI [1])
age
Item
2. age > or = 15 years. those < 15 years of age will be treated under compassionate ind.
boolean
C0001779 (UMLS CUI [1])
zubrod performance status
Item
3. zubrod performance status < or = 2 (ecog scale, appendix a).
boolean
C3714786 (UMLS CUI [1])
liver function
Item
4. adequate liver function (bilirubin < or = to 3.0 mg/dl, unless considered due to tumor), and renal function (creatinine < or = to 3.0 mg/dl, unless considered due to tumor).
boolean
C0005437 (UMLS CUI [1])
C0010294 (UMLS CUI [2])
C0010294 (UMLS CUI [2])
adequate cardiac function
Item
5. adequate cardiac function as assessed clinically by physical examination.
boolean
C0232164 (UMLS CUI [1])
informed consent
Item
6. signed informed consent.
boolean
C0021430 (UMLS CUI [1])
active serious infection
Item
1. active serious infection not controlled by oral or intravenous antibiotics.
boolean
C0009450 (UMLS CUI [1])
investigational antileukemic agent
Item
2. treatment with investigational antileukemic agent or chemotherapy agents in the last 7 days before study entry, unless full recovery from side-effects has occurred or patient has rapidly progressive disease judged life-threatening.
boolean
C0596112 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C1517586 (UMLS CUI [1,2])
active secondary malignancy
Item
3. active secondary malignancy other than skin cancer (e.g. basal cell carcinoma or squamous cell carcinoma) than in investigator's opinion will shorten survival to less than 1 year.
boolean
C0006826 (UMLS CUI [1])
grade iii/iv cardiac problems
Item
4. history of grade iii/iv cardiac problems as defined by the new york heart association criteria.
boolean
C0278962 (UMLS CUI [1])
imatinib mesylate
Item
5. prior history of treatment with imatinib mesylate.
boolean
C0939537 (UMLS CUI [1])
pregnancy or lactating
Item
6. pregnancy or lactating in women of childbearing potential.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])